Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on developing technically-challenging injectable and inhalation products. In addition to its marketed products, the company has a pipeline of 21 generic and proprietary product candidates in various stages of development which target a number of indications.
Exited via Initial Public Offering (NASD: AMPH)
Member count: 1001-5000
Founded date: 1996
Investors 2
| Date | Name | Website |
| - | W Capital ... | wcapgroup.... |
| - | YFY Biotec... | tgbfund.co... |
Mentions in press and media 19
| Date | Title | Description | Category | Author | Source |
| 29.12.2021 | Amphastar ... | Amphastar Receives FDA Tentati... | - | - | marketscre... |
| 09.11.2021 | Amphastar ... | Amphastar Pharmaceuticals Repo... | - | - | marketscre... |
| 09.11.2021 | Financial ... | Amphastar Pharmaceuticals Repo... | - | - | marketscre... |
| 09.11.2021 | Amphastar ... | Amphastar Pharmaceuticals Repo... | - | - | marketscre... |
| 09.11.2021 | Presentati... | Corporate Presentation Novemb... | - | - | marketscre... |
| 28.10.2021 | Amphastar ... | Amphastar Pharmaceuticals to R... | - | - | marketscre... |
| 09.09.2021 | Amphastar ... | 2021 Wells Fargo Virtual Healt... | - | - | marketscre... |
| 27.08.2021 | Amphastar ... | Corporate Presentation August... | - | - | marketscre... |
| 29.07.2021 | Amphastar ... | Amphastar Pharmaceuticals to R... | - | - | marketscre... |
| 06.05.2021 | AMPHASTAR ... | Reports Net Revenues of $103.0... | - | - | marketscre... |
Show more